Sažetak
Uvod/Cilj. Jedna od komplikacija koja se može javiti tokom trudnoće je razvoj preeklampsije (PE). Glavne karakteristike ovog stanja su visok krvni pritisak i vrlo često znaci oštećenja bubrega ili drugih organa. Ovo stanje pogađa 5–7% svih trudnica i jedan je od glavnih faktora morbiditeta i mortaliteta trudnica i fetusa ili novorođenčadi. Cilj ovog rada bio je ispitivanje strukturnih i funkcionalnih modifikacija lipoproteinskih čestica visoke gustine (high-density lipoprotein – HDL) u trudnoćama sa visokim rizikom (TVR) za razvoj PE. Metode. U longitudinalnoj prospektivnoj studiji učestvovala je ukupno 91 trudnica sa TVR od razvoja PE. Od ukupnog broja trudnica, kod njih 71, PE se nije razvila do kraja trudnoće i ova grupa je označena kao grupa bez PE (BPE). Kod preostalih 20 žena sa TVR se razvila PE do porođaja, i one su svrstane u grupu PE. Krv je uzimana za analizu na kraju svakog trimestra i pred porođaj. Raspodela HDL čestica je određivana metodom vertikalne elektroforeze u 3–31% gradijentu poliakrilamidnog gela. Antioksidativni kapacitet HDL čestica je određivan na osnovu aktivnosti enzima paraoksonaze 1 (PON1) vezanog za HDL. Aktivnost PON1 u serumu je određivana metodom kinetičke spektrofotometrije. Rezultati. Rezultati su pokazali da se udeo HDL2b čestica značajno povećao u drugom trimestru (p < 0,05) i ostao je povećan do kraja trudnoće u grupi BPE. Aktivnost PON1 bila je značajno veća u trećem trimestru (p < 0,05) kod ove grupe trudnica. Udeo HDL3a čestica se značajno smanjio u drugom trimestru u PE grupi trudnica (p < 0,05) i ostao je snižen do kraja trudnoće. Aktivnost PON1 enzima u PE gripi se nije menjala u toku trudnoće. Zaključak. Dislipidemija u trudnoći može biti posledica različitih modifikacija HDL čestica. Strukturne i funkcionalne modifikacije HDL čestica, kao jedan od adaptivnih mehanizama, kod trudnica kod kojih se razvila PE, nisu adekvatne i kao takve gube svoju ateroprotektivnu ulogu.
Ključne reči
Array
Array
Array
Reference
1. Tranquilli AL, Dekker G, Magee L, Roberts J, Sibai BM, Steyn W, et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: a revised statement from the ISSHP. Pregnancy Hypertens 2014; 4(2): 97–104.
2. Abalos E, Cuesta C, Grosso AL, Chou D, Say L. Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol Reprod Biol 2013; 170(1): 1–7.
3. Romero R, Chaiworapongsa T. Preeclampsia: a link between trophoblast dysregulation and an antiangiogenic state. J Clin Invest 2013; 123(7): 2775–7.
4. Kaaja R. Lipid abnormalities in pre-eclampsia: implications for vascular health. Clin Lipidol 2011; 6(1): 71–8.
5. Spracklen CN, Smith CJ, Saftlas AF, Robinson JG, Ryckman KK. Maternal hyperlipidemia and the risk of preeclampsia: a meta-analysis. Am J Epidemiol 2014; 180(4): 346‒58.
6. Konrad E, Güralp O, Shaalan W, Elzarkaa AA, Moftah R, Alemam D, et al. Correlation of elevated levels of lipoprotein(a), high-density lipoprotein and low-density lipoprotein with severity of preeclampsia: a prospective longitudinal study. J Obstet Gynaecol 2020; 40(1): 53‒8.
7. Sandsæter HL, Horn J, Rich-Edwards JW, Haugdahl HS. Preeclampsia, gestational diabetes and later risk of cardiovascular disease: Women’s experiences and motivation for lifestyle changes explored in focus group interviews. BMC Pregnancy Childbirth 2019; 19: 448.
8. Shah AS, Tan L, Long JL, Davidson WS. Proteomic diversity of high-density lipoproteins: our emerging understanding of its importance in lipid transport and beyond. J Lipid Res 2013; 54(10): 2575–85.
9. Ben-Aicha S, Badimon L, Vilahur G. Advances in HDL: Much More than Lipid Transporters. Int J Mol Sci 2020; 21(3): 732.
10. Stadler JT, Wadsack C, Marsche G. Fetal High-Density Lipoproteins: Current Knowledge on Particle Metabolism, Composition and Function in Health and Disease. Biomedicines 2021; 9(4): 349.
11. Kontush A. HDL particle number and size as predictors of cardiovascular disease. Front Pharmacol 2015; 6: 218.
12. Kontush A, Chapman MJ. Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. Curr Opin Lipidol 2010; 21(4): 312–8.
13. Sulaiman WNW, Caslake MJ, Delles C, Karlsson H, Mudler MT, Graham D et al. Does high-density lipoprotein protect vascular function in healthy pregnancy? Clin Sci (Lond) 2016; 130(7): 491–7.
14. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol 2013; 122(5): 1122‒31.
15. National Institute for Health and Care Excellence. Hypertension in pregnancy: diagnosis and management. NICE guideline. Available from: www.nice.org.uk/guidance/ng133 (2019 June 25).
16. Friedwald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18(6): 499–502.
17. Dobiásová M. Atherogenic index of plasma [log(triglycerides/HDL-cholesterol)]: theoretical and practical implications. Clin Chem 2004; 50(7): 1113‒5.
18. Vekic J, Topic A, Zeljkovic A, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V. LDL and HDL subclasses and their relationship with Framingham risk score in middle-aged Serbian population. Clin Biochem 2007; 40(5): 310–6.
19. Blanche PJ, Gong EL, Forte TM, Nichols AV. Characterization of human high-density lipoproteins by gradient gel electrophoresis. Biochim Biophys Acta 1981; 665(3): 408–19.
20. Richter RJ, Furlong CE. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 1999; 9(6): 745–53.
21. Kotur-Stevuljevic J, Spasic S, Stefanovic A, Zeljkovic A, Bogavac-Stanojevic N, Kalimanovska-Oštrić D, et al. Paraoxonase-1 (PON1) activity, but not PON1(Q192R) phenotype, is a predictor of coronary artery disease in a middle-aged Serbian population. Clin Chem Lab Med 2006; 44(10): 1206‒13.
22. Wild R, Weedin EA, Wilson D. Dyslipidemia in Pregnancy. Cardiol Clin 2015; 33(2): 209–15.
23. Zeng Z, Liu F, Li S. Metabolic Adaptations in Pregnancy: A Review. Ann Nutr Metab 2017; 70(1): 59–65.
24. Alahakoon TI, Medbury HJ, Williams H, Lee VW. Lipid profiling in maternal and fetal circulations in preeclampsia and fetal growth restriction-a prospective case control observational study. BMC Pregnancy Childbirth 2020; 20(1): 61.
25. Ardalić D, Stefanović A, Banjac G, Cabunac P, Miljković M, Mandić-Marković V, et al. Lipid profile and lipid oxidative modification parameters in the first trimester of high- risk pregnancies - possibilities for preeclampsia prediction. Clin Biochem 2020; 81: 34‒40.
26. Zeljkovic A, Vekic J, Spasic S, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V, Gojkovic T, et al. Changes in LDL and HDL subclasses in normal pregnancy and associations with birth weight, birth length and head circumference. Matern Child Health J 2013; 17(3): 556‒65.
27. Alvarez JJ, Montelongo A, Iglesias A, Lasunción MA, Herrera E. Longitudinal study on lipoprotein profile, high density lipoprotein subclass, and postheparin lipases during gestation in women. J Lipid Res 1996; 37(2): 299‒308.
28. Silliman K, Shore V, Forte TM. Hypertriglyceridemia during late pregnancy is associated with the formation of small dense low-density lipoproteins and the presence of large buoyant high-density lipoproteins. Metabolism 1994; 43(8): 1035‒41.
29. Kim DS, Marsillach J, Furlong CE, Jarvik GP. Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease. Pharmacogenomics 2013; 14(12): 1495‒515.
30. Besler C, Heinrich K, Rohrer L, Doerries C, Riwanto M, Shis DM, et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest 2011; 121(7): 2693–708.
31. Roy AC, Loke DF, Saha N, Viegas OA, Tay JS, Ratnam SS. Interrelationships of serum paraoxonase, serum lipids and apolipoproteins in normal pregnancy. A longitudinal study. Gynecol Obstet Invest 1994; 38(1): 10–33.
32. León-Reyes G, Maida-Claros RF, Urrutia-Medina AX, Jorge-Galarza E, Guzmán-Grenfell AM, Fuentes-García S, et al. Oxidative profiles of LDL and HDL isolated from women with preeclampsia. Lipids Health Dis 2017; 16(1): 90.
33. Stefanovic A, Ardalic D, Kotur-Stevuljevic J, Vujovic A, Spasic S, Spasojevic-Kalimanovska V, et al. Longitudinal changes in PON1 activities, PON1 phenotype distribution and oxidative status throughout normal pregnancy. Reprod Toxicol 2012; 33(1): 20–6.
34. Uzun H, Benian A, Madazli R, Topçuoğlu MA, Aydin S, Albayrak M. Circulating oxidized low-density lipo-protein and paraoxanase activity preeclampsia. Gynecol Obstet Invest 2005; 60(4): 195–200.